VA Backs $4.9M in Groundwork for Ibogaine PTSD Studies

The federal government is putting money behind a psychedelic drug that veterans groups have been asking it to take seriously for years, and this time the funding is coming from inside the Trump administration itself.

Snapshot

Health Secretary Robert F. Kennedy Jr. announced up to $4.9 million to prepare for the first U.S. studies of ibogaine for PTSD, according to the Associated Press. The money funds manufacturing, dosing and study design rather than patient trials, with Veterans Affairs Secretary Doug Collins joining the announcement and calling for safety-first, "best-in-class research."

Key points

• What's funded: The $4.9 million covers groundwork — drug manufacturing, dosing protocols and study design — not direct human testing, per Kennedy.
• Data source: The government will draw on treatment data and guidance from Beond Inc., a Texas-based company that has treated over 3,000 patients with ibogaine in Mexico, where the drug is legal.
• Real risks: Ibogaine, derived from a West African shrub, can cause hallucinations, vomiting, tremors and potentially fatal heart-rhythm problems, and remains federally illegal alongside LSD and MDMA.
• Why it matters to veterans: Collins said veterans with PTSD are "owed" urgency and rigorous science, reflecting pressure from veterans who have already traveled abroad for ibogaine therapy costing $10,000 to $20,000 per course.
• Political backstory: The push traces to an April executive order from President Trump, reportedly spurred by a text exchange with podcaster Joe Rogan, who had discussed ibogaine on his show.

Quick take

This is a funding and groundwork announcement, not an approval — ibogaine stays illegal and unproven by rigorous U.S. trial standards for now. For veterans frustrated with existing PTSD treatment options, it signals that federal research doors are finally opening, but the serious cardiac risks mean this will be a slow, carefully monitored process rather than a fast track to a new VA treatment.

Read the full story: military.com